What Is Cannabigerol (CBG)?
Cannabigerol, abbreviated CBG, is a non-intoxicating phytocannabinoid produced in trace amounts by the Cannabis sativa plant. It is most notable to researchers because its acidic form, cannabigerolic acid (CBGA), serves as the biosynthetic precursor to nearly every other major cannabinoid the plant produces, including tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabichromene (CBC) (Gagne et al., 2012; Pollastro et al., 2018). For that reason, CBG is often nicknamed the “mother cannabinoid.”
CBG itself is present in mature cannabis flower at concentrations typically below 1%, because most CBGA is enzymatically converted into other cannabinoid acids during the plant’s flowering cycle (Nachnani et al., 2021). Selectively bred chemovars and early-harvest hemp can produce higher CBG yields, which is why interest in the compound as an isolated ingredient has grown alongside the broader cannabinoid market.
This article reviews what the peer-reviewed scientific literature currently shows about CBG: how it interacts with the body, what areas of research show the most preclinical promise, and what limited human data exist. It is intended as an educational overview, not medical advice.
How CBG Is Made: Biosynthesis at a Glance
In the cannabis plant, CBG begins its life as cannabigerolic acid (CBGA). CBGA is synthesized when the enzyme aromatic prenyltransferase joins olivetolic acid with geranyl pyrophosphate (Gagne et al., 2012). From there, three plant enzymes — THCA synthase, CBDA synthase, and CBCA synthase — compete for CBGA as a substrate, converting it into the acidic forms of THC, CBD, and CBC respectively. CBGA that escapes these enzymatic pathways slowly decarboxylates over time (especially with heat or UV exposure) into neutral CBG (Citti et al., 2019).
Because CBGA is consumed to produce other cannabinoids, late-flowering, high-THC plants typically contain very little remaining CBG. High-CBG chemovars are bred to either delay or partially block this enzymatic conversion.
CBG’s Pharmacology: Receptor and Channel Activity
CBG has a relatively complex pharmacological profile. Although it is structurally a cannabinoid, it does not behave like THC at the body’s main cannabinoid receptors.
Cannabinoid receptors (CB1 and CB2). CBG binds CB1 and CB2 with much lower affinity than THC — roughly 5-fold and 27-fold lower, respectively (Navarro et al., 2018). Functional studies show that CBG behaves as a partial agonist or weak partial agonist at CB2 and acts as a modulator (rather than a strong activator) at CB1. Notably, Navarro et al. (2018) demonstrated that CBG can also modulate signaling at CB1–CB2 heteromer complexes, where it appears to blunt the activity of stronger agonists.
Transient receptor potential (TRP) channels. CBG is a more potent ligand at several TRP “thermo-sensors” than at CB1 or CB2. De Petrocellis et al. (2011) reported that CBG activates TRPA1, TRPV1, and TRPV2, and antagonizes TRPM8 with an IC₅₀ near 160 nM. TRPM8 is implicated in cold/menthol sensation and certain cancer pathways, and it has been a focus of CBG-related cancer research.
Other targets. Independent studies have shown that CBG can inhibit anandamide reuptake and the endocannabinoid-degrading enzyme FAAH, which would be expected to raise tissue levels of the endocannabinoid anandamide (Cascio et al., 2010). CBG also activates the nuclear receptor PPARγ at micromolar concentrations and antagonizes the 5-HT1A serotonin receptor (Cascio et al., 2010; Nachnani et al., 2021). The 5-HT1A interaction is one of the proposed mechanisms behind CBG’s anti-emetic and anxiolytic effects observed in animal models.
The take-home message is that CBG is best described as a multi-target compound rather than a classical cannabinoid receptor agonist. That polypharmacology underlies the breadth of preclinical research described below — and also makes mechanistic conclusions harder to draw.
Areas of Preclinical Research
Most of what is known about CBG comes from cell culture and animal studies. These are useful for generating hypotheses but cannot be assumed to translate to humans without controlled clinical trials.
Neuroprotection
Valdeolivas et al. (2015) tested CBG in two mouse models of Huntington’s disease — R6/2 transgenic mice and 3-nitropropionate-lesioned mice. CBG reduced motor deficits, preserved striatal neurons, attenuated reactive microgliosis, and partially normalized the expression of genes linked to Huntington’s pathology. The authors attributed the effect to antioxidant and anti-inflammatory mechanisms rather than to direct CB1/CB2 binding. CBG has also been investigated more recently for ischemic and inflammatory neurological insults, with similar antioxidant and anti-microglial findings (Aguareles et al., 2025).
Inflammatory bowel disease
Borrelli et al. (2013) reported that CBG reduced markers of colitis severity in a dinitrobenzene sulfonic acid (DNBS) mouse model. Specifically, CBG decreased colon weight–to–length ratio, lowered myeloperoxidase activity and inducible nitric oxide synthase (iNOS) expression, increased superoxide dismutase activity, and normalized interleukin-1β, IL-10, and interferon-γ. Subsequent work using high-CBG hemp extracts has shown comparable signals in different colitis models (Henderson et al., 2024).
Antibacterial activity
Appendino et al. (2008) screened five major cannabinoids — CBD, CBC, CBG, THC, and CBN — against six clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). All five showed minimum inhibitory concentrations (MICs) of about 1–2 µg/mL, which is comparable to vancomycin. CBG has since been tested against other pathogens, including Streptococcus mutans (an oral cavity organism), with similar activity (Aqawi et al., 2021). These remain in vitro findings; CBG has not been studied as a clinical antimicrobial.
Oncology research
Borrelli et al. (2014) reported that CBG inhibited colorectal cancer cell growth in vitro and reduced tumor growth in xenograft and chemically induced colon carcinogenesis models in mice, an effect they attributed in part to TRPM8 antagonism. More recent work in glioblastoma cell lines has shown that CBG impairs invasion and viability of glioblastoma stem cells, with proposed contributions from GPR55 and TRPV1 signaling (Lah et al., 2021; Lah et al., 2022). These results are preclinical and should not be interpreted as evidence that CBG treats cancer in humans.
Other preclinical areas
Smaller bodies of literature exist for CBG in metabolic syndrome, intraocular pressure modulation, bladder contractility, and pain — most of it from a single laboratory or a small set of in vitro experiments. A comprehensive 2024 review by Nachnani and colleagues catalogues these findings and emphasizes that the preclinical CBG literature is broad but generally shallow (Calapai et al., 2022; Nachnani et al., 2021).
What the Limited Human Data Show
Direct clinical research on isolated CBG in humans is still in its early stages. As of the time of writing, only a small number of controlled trials have been published.
The most cited is Cuttler et al. (2024), a double-blind, placebo-controlled, crossover field trial in which 34 healthy adults received either 20 mg of hemp-derived CBG or placebo on two separate sessions. Compared with placebo, CBG was associated with statistically significant reductions in self-reported anxiety and stress, along with a measurable improvement on a verbal memory task. Participants did not report intoxication or motor impairment, and adverse events were mild and infrequent.
A separate observational survey by Russo et al. (2022) collected self-report data from 127 adults using CBG-predominant cannabis products and found that respondents most commonly reported using it for anxiety, chronic pain, depression, and insomnia — though, as the authors stress, survey data of this kind cannot establish efficacy.
These studies are encouraging but small. They do not establish that CBG is effective for any specific medical condition, and they do not address dose response, long-term safety, or interactions with prescription medications.
Safety, Drug Interactions, and What’s Not Known
CBG has not been associated with intoxication in any published trial, and acute adverse-event profiles in humans have been mild. However, several practical knowledge gaps remain:
- Cytochrome P450 interactions. CBG inhibits several CYP450 enzymes in vitro, suggesting it may affect the metabolism of common prescription drugs (Nasrin et al., 2021). This has not been characterized in clinical pharmacokinetic studies.
- Long-term safety. No published study has examined chronic CBG dosing in humans for more than a few weeks.
- Pregnancy and lactation. No human safety data exist; CBG should be avoided in these populations.
- Product variability. Hemp-derived CBG products are not standardized, and independent testing has occasionally found discrepancies between labeled and measured cannabinoid content (Bonn-Miller et al., 2017).
The U.S. Food and Drug Administration has not approved CBG for the treatment, prevention, cure, or diagnosis of any medical condition. Anyone considering CBG, particularly alongside prescription medications, should speak with a qualified medical professional first.
Frequently Asked Questions
Is CBG psychoactive?
In the published peer-reviewed literature, isolated CBG has not produced THC-like intoxication in either animal models or the small human trials conducted to date (Cuttler et al., 2024). It is best classified as non-intoxicating.
How is CBG different from CBD?
CBG and CBD are both non-intoxicating phytocannabinoids, but they differ structurally and pharmacologically. CBD has more extensive clinical data, including FDA approval (as Epidiolex) for specific seizure disorders, while CBG remains primarily a preclinical research compound. They engage different receptor and channel targets and likely have different effect profiles, although direct head-to-head clinical comparisons are sparse.
Why is CBG called the “mother cannabinoid”?
Because its acidic form, CBGA, is the biosynthetic precursor that the cannabis plant uses to produce the acidic forms of THC, CBD, and CBC (Gagne et al., 2012). Mature, high-THC plants typically contain very little remaining CBG because it has been enzymatically converted into other cannabinoids during flowering.
Does CBG show up on a drug test?
Standard workplace drug screens look for THC and its metabolite, not CBG. However, CBG products derived from full-spectrum hemp can contain trace amounts of THC, which could theoretically contribute to a positive screen. Anyone subject to drug testing should choose products with verified third-party lab results and discuss any concerns with their employer or testing program.
References
Aguareles, J., García-Rincón, D., Vázquez-Villoldo, N., Costas-Insua, C., Ruiz de Martín Esteban, S., Hernández-Galilea, E., Romero, J., Martínez-Orgado, J., & Galve-Roperh, I. (2025). Cannabigerol attenuates memory impairments, neurodegeneration, and neuroinflammation caused by transient global cerebral ischemia in mice. International Journal of Molecular Sciences, 26(16), 8056.
Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., Smith, E., & Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure–activity study. Journal of Natural Products, 71(8), 1427–1430. https://doi.org/10.1021/np8002673
Aqawi, M., Sionov, R. V., Gallily, R., Friedman, M., & Steinberg, D. (2021). Anti-bacterial properties of cannabigerol toward Streptococcus mutans. Frontiers in Microbiology, 12, 656471. https://doi.org/10.3389/fmicb.2021.656471
Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709. https://doi.org/10.1001/jama.2017.11909
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., Orlando, P., Battista, G., Pagano, E., Di Marzo, V., & Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316. https://doi.org/10.1016/j.bcp.2013.01.017
Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., De Petrocellis, L., Buono, L., Orlando, P., & Izzo, A. A. (2014). Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35(12), 2787–2797. https://doi.org/10.1093/carcin/bgu205
Calapai, F., Cardia, L., Esposito, E., Ammendolia, I., Mondello, C., Lo Giudice, R., Gangemi, S., Calapai, G., & Mannucci, C. (2022). Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evidence-Based Complementary and Alternative Medicine, 2022, 3336516.
Cascio, M. G., Gauson, L. A., Stevenson, L. A., Ross, R. A., & Pertwee, R. G. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129–141. https://doi.org/10.1111/j.1476-5381.2009.00515.x
Citti, C., Linciano, P., Russo, F., Luongo, L., Iannotta, M., Maione, S., Laganà, A., Capriotti, A. L., Forni, F., Vandelli, M. A., Gigli, G., & Cannazza, G. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ⁹-tetrahydrocannabinol: Δ⁹-tetrahydrocannabiphorol. Scientific Reports, 9(1), 20335. https://doi.org/10.1038/s41598-019-56785-1
Cuttler, C., Stueber, A., Cooper, Z. D., & Russo, E. (2024). Acute effects of cannabigerol on anxiety, stress, and mood: A double-blind, placebo-controlled, crossover, field trial. Scientific Reports, 14(1), 16042. https://doi.org/10.1038/s41598-024-66879-0
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494. https://doi.org/10.1111/j.1476-5381.2010.01166.x
Gagne, S. J., Stout, J. M., Liu, E., Boubakir, Z., Clark, S. M., & Page, J. E. (2012). Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides. Proceedings of the National Academy of Sciences, 109(31), 12811–12816. https://doi.org/10.1073/pnas.1200330109
Henderson, R. G., Welsh, B. T., Rogers, J. M., Borghoff, S. J., Trexler, K. R., Bonn-Miller, M. O., & Lefever, T. W. (2024). High cannabigerol hemp extract moderates colitis and modulates the microbiome in an inflammatory bowel disease model. Journal of Pharmacology and Experimental Therapeutics, 391(1), 1–12. https://doi.org/10.1124/jpet.123.001939
Lah, T. T., Novak, M., Pena Almidon, M. A., Marinelli, O., Žvar Baškovič, B., Majc, B., Mlinar, M., Bošnjak, R., Breznik, B., Zomer, R., & Nabissi, M. (2021). Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma. Cells, 10(2), 340. https://doi.org/10.3390/cells10020340
Lah, T. T., Majc, B., Novak, M., Sušnik, A., Breznik, B., Porčnik, A., Bošnjak, R., Sadikov, A., Malavolta, M., & Halilčević, S. (2022). The cytotoxic effects of cannabidiol and cannabigerol on glioblastoma stem cells may mostly involve GPR55 and TRPV1 signalling. Cancers, 14(23), 5918. https://doi.org/10.3390/cancers14235918
Nachnani, R., Raup-Konsavage, W. M., & Vrana, K. E. (2021). The pharmacological case for cannabigerol. Journal of Pharmacology and Experimental Therapeutics, 376(2), 204–212. https://doi.org/10.1124/jpet.120.000340
Nasrin, S., Watson, C. J. W., Perez-Paramo, Y. X., & Lazarus, P. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis–drug interactions. Drug Metabolism and Disposition, 49(12), 1070–1080. https://doi.org/10.1124/dmd.121.000442
Navarro, G., Varani, K., Reyes-Resina, I., Sánchez de Medina, V., Rivas-Santisteban, R., Sánchez-Carnerero Callado, C., Vincenzi, F., Casano, S., Ferreiro-Vera, C., Canela, E. I., Borea, P. A., Nadal, X., & Franco, R. (2018). Cannabigerol action at cannabinoid CB1 and CB2 receptors and at CB1–CB2 heteroreceptor complexes. Frontiers in Pharmacology, 9, 632. https://doi.org/10.3389/fphar.2018.00632
Pollastro, F., Caprioglio, D., Del Prete, D., Rogati, F., Minassi, A., Taglialatela-Scafati, O., Munoz, E., & Appendino, G. (2018). Cannabichromene. Natural Product Communications, 13(9), 1189–1194.
Russo, E. B., Cuttler, C., Cooper, Z. D., Stueber, A., Whiteley, V. L., & Sexton, M. (2022). Survey of patients employing cannabigerol-predominant cannabis preparations: Perceived medical effects, adverse events, and withdrawal symptoms. Cannabis and Cannabinoid Research, 7(5), 706–716. https://doi.org/10.1089/can.2021.0058
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: Studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185–199. https://doi.org/10.1007/s13311-014-0304-z
